HRMY
Companies
NASDAQ
Harmony Biosciences Holdings, Inc.
Health Care
$32.48
-$1.93 (-5.61%)
Price Chart
Overview
About HRMY
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Market Cap
$1.7B
Volume
22.6M
Avg. Volume
23.8M
P/E Ratio
10.92638
Dividend Yield
0.00%
Employees
233.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.60
Low Correlation
Volatility
High (0.51)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, HRMY shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.7B
Volume22.6M
P/E Ratio10.93
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 6, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025